Sitagliptin for Reducing Inflammation and Immune Activation
Condition(s):HIV-1 InfectionLast Updated:June 18, 2018Completed
Hide Studies Not Open or Pending
Condition(s):HIV-1 InfectionLast Updated:June 18, 2018Completed
Condition(s):Diabetes Mellitus, Type 2; Renal Insufficiency, ChronicLast Updated:May 12, 2017Completed
Condition(s):Glucose IntoleranceLast Updated:January 18, 2020Completed
Condition(s):Type 2 Diabetes MellitusLast Updated:June 22, 2021Completed
Condition(s):Diabetes; AtherosclerosisLast Updated:October 21, 2016Completed
Condition(s):Type 2 Diabetes MellitusLast Updated:November 20, 2018Completed
Condition(s):Diabetes Mellitus, Type 2Last Updated:January 2, 2017Completed
Condition(s):Diabetes Mellitus, Type 1Last Updated:August 7, 2018Completed
Condition(s):Type 2 Diabetes MellitusLast Updated:May 30, 2017Completed
Condition(s):Obesity; PreDiabetesLast Updated:October 18, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.